cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Intercept Pharmaceuticals Inc
15 own
15 watching
Current Price
$0
$-0.44
(-2.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
899.17M
52-Week High
52-Week High
21.86
52-Week Low
52-Week Low
10.81
Average Volume
Average Volume
0.15M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization899.17M
icon52-Week High21.86
icon52-Week Low10.81
iconAverage Volume0.15M
iconDividend Yield--
iconP/E Ratio--
What does the Intercept Pharmaceuticals Inc do?
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.
Read More
How much money does Intercept Pharmaceuticals Inc make?
News & Events about Intercept Pharmaceuticals Inc.
Globe Newswire
20days ago
NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCAs improvement in liver fibrosis without worsening of NASHPDUFA target action date set for June 22, 2023 MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE ...
Globe Newswire
1month ago
MORRISTOWN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...
Globe Newswire
1month ago
MORRISTOWN, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA...
Globe Newswire
1month ago
NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with nearly 1,000 patients on study drug for 4 years MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- ...
Globe Newswire
2 months ago
MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Intercept Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Intercept Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Intercept Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Intercept Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Intercept Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Intercept Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Intercept Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Intercept Pharmaceuticals Inc?
plus_minus_icon
What percentage is Intercept Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Intercept Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.44
(-2.03%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00